were hospitalized due to SIADH, HN at admission was â¤130 mEq/l in 94.3%. Median ... started tolvaptan 15 mg/daily, 4 started with 30 mg and 14 with 7.5 mg.
Annals of Oncology 25 (Supplement 4): iv517–iv541, 2014 doi:10.1093/annonc/mdu356.63
supportive care 1543P
SYNDROME OF INAPPROPRIATE ANTI-DIURETIC HORMONE SECRETION (SIADH) IN CANCER PATIENTS (PTS): RESULTS OF THE FIRST MULTICENTER ITALIAN SURVEY
abstracts
Downloaded from http://annonc.oxfordjournals.org/ by guest on October 20, 2014
R. Berardi1, M. Caramanti1, E. Arvat2, C. Mastroianni3, F. Agustoni4, M. Tiseo5, B. Vincenzi6, R. Buosi7, R. Chiari8, A. Camerini9, A. Galeassi10, M. Ghidini11, V. De Marino12, D. Ferrari13, L. Doni14, D. Fumagalli15, L. Portalone16, G. Schinzari17, M. Tucci18, S. Cascinu1 1 Clinica di Oncologia Medica, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, ITALY 2 Div. Oncological Endocrinology, Dept. Medical Sciences, University of Turin, Turin, ITALY 3 Medical Oncology, Azienda Ospedaliera di Cosenza, Cosenza, ITALY 4 Oncologia Medica Toraco Polmonare, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, ITALY 5 Oncologia Medica, Azienda Ospedaliero-Universitaria, Parma, Parma, ITALY 6 Medical Oncology, University Campus Bio-Medico, Rome, ITALY 7 SCDU Oncologia Medica, Azienda Ospedaliera Universitaria Maggiore della Carità, Università del Piemonte Orientale Amedeo Avogadro, Novara, ITALY 8 Medical Oncology, Ospedale S. Maria della Misericordia, Perugia, ITALY 9 U.O.C. Oncologia Medica, Ospedale "Versilia", Lido di Camaiore, ITALY 10 Humanitas Cancer Center, Humanitas Cancer Center, Rozzano, ITALY 11 Humanitas Mater Domini, Humanitas Mater Domini, Castellanza, ITALY 12 Oncologia Medica, Ospedale Monaldi, Naples, ITALY 13 Oncologia, Ospedale San Paolo, Milan, ITALY 14 Oncology Division, AOU Careggi, Florence, ITALY 15 U.O. Oncologia, Multimedica, Sesto San Giovanni (MI), ITALY 16 Pneumologia Oncologica 2, Azienda Ospedaliera S. Camillo Forlanini, Rome, ITALY 17 Oncologia Medica, Università Cattolica del Sacro Cuore, Rome, ITALY 18 SCDU Oncologia Medica, AOU San Luigi Gonzaga, Orbassano (TO), ITALY
Aim: SIADH may be related to several causes ( pulmonary disorders, CNS disturbances, drugs and chemotherapeutic agents), but in the majority of cases it is caused by malignancies. This observational study aimed to analyze treatments and outcome of SIADH in cancer pts. Methods: This study includes 69 consecutive cancer pts who experienced SIADH between 2010 and 2014 in 22 Italian Cancer Centers. Data on clinico-pathology, anticancer and SIADH treatments were recorded and statistically analized. Results: M/F ratio was 47/22, median age was 67 years (range 37-83). Primary tumor was lung cancer in 50 pts (SCLC in 39), while it was GI cancer in 8 pts. Fifty-eight pts were hospitalized due to SIADH, HN at admission was ≤130 mEq/l in 94.3%. Median duration of hospitalization was 13 days (range 3-90). 31 pts received tolvaptan for SIADH treatment (group A); other treatments included hypertonic saline solutions, diuretics, fluids restriction (group B). Group A included a significant higher N° of lung cancer pts (77.4% vs 68.4%) with metastatic disease (80.6% vs 76.3%). Moreover pts in group A had more severe HN at admission: serum sodium was ≤130 mEq/l in 96.7% pts and
